Back Hepatitis C

Hepatitis C

Boceprevir Label Information Updated to Include Acute Hypersensitivity Risk

Package information for the recently approved HCV protease inhibitor boceprevir (Victrelis) was recently updated to include post-marketing data about the risk of serious hypersensitivity, or allergic reactions, among hepatitis C patients taking it as part of triple therapy with pegylated interferon and ribavirin. People who experience hypersensitivity symptoms including itching, hives, swelling of the face, tongue, or throat, or trouble breathing or swallowing should seek prompt medical attention.alt

Vertex Announces Agreements to Develop Interferon-free VX-135 Regimens for Hepatitis C

Vertex Pharmaceuticals this week announced that it has made separate agreements with Janssen Pharmaceuticals and GlaxoSmithKline (GSK) to evaluate all-oral regimens containing its HCV polymerase inhibitor VX-135 (also known as ALS-2200) for previously untreated genotype 1 chronic hepatitis C patients.alt

ICAAC 2012: Hepatitis C Can Be Successfully Treated in Injection Drugs Users with or without HIV

HIV negative and HIV positive chronic hepatitis patients  in Vancouver with a history of injection drug use -- most of whom were on methadone maintenance -- achieved sustained response rates with interferon-based therapy similar to those of non-users, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. alt

Bacterial Translocation Linked to Severe Liver Disease among HIV/HCV Coinfected People

HIV positive people with hepatitis C coinfection who had evidence of intestinal bacteria in their blood -- known as bacterial translocation -- had more advanced liver fibrosis and faster fibrosis progression, researchers reported in the August 28, 2012, advance edition of the Journal of Acquired Immune Deficiency Syndromes. alt

ICAAC 2012: Infections are Common among HIV/HCV Coinfected Patients on Interferon

Life-threatening infections occur frequently among people with HIV and hepatitis C virus (HCV) coinfection during treatment with pegylated interferon plus ribavirin, but this does not appear to be a consequence of neutropenia, or loss of white blood cells, according to a poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this month on San Francisco. alt

Antiviral Therapy for Hepatitis C, Especially with Sustained Response, Lowers Liver Cancer Risk

Interferon-based antiviral therapy lowers the likelihood that people with liver fibrosis or cirrhosis due to chronic hepatitis C will develop hepatocellular carcinoma (HCC), with the greatest risk reduction seen among those who achieve virological response, according to a study described in the October 22, 2012, edition of open-access online journal BMJ Open. alt

Interferon-free HCV Treatment: Simeprevir and ALS-2200 Enter Phase 2 All-oral Studies

A trio of interferon-free, all-oral regimens for treatment of chronic hepatitis C virus (HCV) are entering Phase 2 clinical trials, the intermediate stage of development after basic safety and antiviral activity have been established, according to recent press releases from Medivir and Vertex. alt

4-Drug Oral Regimen Cures More than 90% of Chronic Hepatitis C Patients

An all-oral, interferon-free combination regimen containing 3 experimental direct-acting hepatitis C virus (HCV) drugs from Abbott plus ribavirin produced sustained virological response in 99% of previously untreated people with genotype 1 chronic hepatitis C and 93% of patients who experienced prior failure of interferon-based therapy, according to preliminary data from the ongoing Aviator study.alt

ICAAC 2012: HCV Polymerase Inhibitor Sofosbuvir Appears Safe and Effective for HIV/HCV Coinfected People

HIV/altHCV coinfected people taking the experimental hepatitis C virus (HCV) polymerase inhibitor sofosbuvir (formerly GS-7977) experienced a rapid decline in HCV viral load similar to that seen in HIV negative patients, researchers reported this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. Side effects were also similar, and there was no sign of interactions with antiretroviral drugs in this 14-day study